

# Imugene Ltd

08:44 28 Feb 2020

## Imugene outlines its focus on developing immunology treatments in half-yearly report

Imugene Ltd's (ASX:IMU) focus of operations in the short to medium term will be directed towards the development of CF33 and PD1-Vaxx in a first in human studies as well as continued enrolment of the HER-Vaxx phase-2 study, as highlighted in its latest half-year report.

### CF33 - a chimeric poxvirus

CF33 is a chimeric poxvirus derived through recombination among multiple strains of vaccinia virus and other species of poxvirus, making it better than a virus based on a single strain.

Preclinical data has demonstrated that CF33 is more efficacious than all parental viruses and some viruses in clinical trials.

CF33 efficiently shrank injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.

### PD1-Vaxx study to begin in 2020

The company's PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

PD1-Vaxx will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

### HER-Vaxx trial targeting HER-2 positive gastric cancer

The HER-Vaxx trial is targeting HER-2 positive gastric cancer, which was selected for this study as this type is not nearly as well served as breast cancer.

The Phase 1b stage of the study has been completed testing three different doses of the HER-Vaxx vaccine in combination with chemotherapy.

Phase 1b study met all key endpoints to identify the optimal dose of HER-Vaxx for the phase-2 study and Imugene continues to monitor the enrolment, data collection and the patient's immune responses to the vaccine.


The company presented the Phase 1b study results of its HER-Vaxx B-cell immunotherapies at several international conferences around the world such as Chicago, Barcelona and Singapore during 2019.

Further patient data from Phase 1b will be published or presented at international conferences in 2020.

**Price:** 0.034

**Market Cap:** \$150.48 m

### 1 Year Share Price Graph



### Share Information

**Code:** IMU

**Listing:** ASX

**52 week High Low**  
0.063 0.013

**Sector:** Pharma & Biotech

**Website:** www.imugene.com

### Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).